Literature DB >> 20019219

The role of DAT-SPECT in movement disorders.

G Kägi1, K P Bhatia, E Tolosa.   

Abstract

Dopamine transporter (DAT) imaging is a sensitive method to detect presynaptic dopamine neuronal dysfunction, which is a hallmark of neurodegenerative parkinsonism. DAT imaging can therefore assist the differentiation between conditions with and without presynaptic dopaminergic deficit. Diagnosis of Parkinson disease or tremor disorders can be achieved with high degrees of accuracy in cases with full expression of classical clinical features; however, diagnosis can be difficult, since there is a substantial clinical overlap especially in monosymptomatic tremor (dystonic tremor, essential tremor, Parkinson tremor). The use of DAT-SPECT can prove or excludes with high sensitivity nigrostriatal dysfunction in those cases and facilitates early and accurate diagnosis. Furthermore, a normal DAT-SPECT is helpful in supporting a diagnosis of drug-induced-, psychogenic- and vascular parkinsonism by excluding underlying true nigrostriatal dysfunction. This review addresses the value of DAT-SPECT and its impact on diagnostic accuracy in movement disorders presenting with tremor and/or parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20019219     DOI: 10.1136/jnnp.2008.157370

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  72 in total

1.  [123I] FP-CIT SPECT in Creutzfeldt-Jakob disease.

Authors:  Dimitri Renard; Laurent Collombier; Xavier Ayrignac; Florence Bouttier; Pierre-Olivier Kotzki; Pierre Labauge
Journal:  J Neurol       Date:  2010-06-17       Impact factor: 4.849

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.

Authors:  Keita Kuya; Yuki Shinohara; Fuminori Miyoshi; Shinya Fujii; Yoshio Tanabe; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2016-01-16       Impact factor: 2.804

4.  Distinct spatiotemporal patterns for disease duration and stage in Parkinson's disease.

Authors:  Simon Badoud; Nicolas Nicastro; Valentina Garibotto; Pierre R Burkhard; Sven Haller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-29       Impact factor: 9.236

Review 5.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 6.  Functional (psychogenic) movement disorders.

Authors:  Kathrin Czarnecki; Mark Hallett
Journal:  Curr Opin Neurol       Date:  2012-08       Impact factor: 5.710

7.  Abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Florian Holtbernd; Jean-François Gagnon; Ron B Postuma; Yilong Ma; Chris C Tang; Andrew Feigin; Vijay Dhawan; Mélanie Vendette; Jean-Paul Soucy; David Eidelberg; Jacques Montplaisir
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 9.  Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Authors:  Toshihide Ogawa; Shinya Fujii; Keita Kuya; Shin-Ichiro Kitao; Yuki Shinohara; Mana Ishibashi; Yoshio Tanabe
Journal:  Yonago Acta Med       Date:  2018-09-26       Impact factor: 1.641

10.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.